TARRYTOWN, N.Y., Sept. 1 /PRNewswire-FirstCall/ -- Emisphere Technologies,
Inc. (Nasdaq: EMIS), today announced that it will participate in the
Oppenheimer Diabetes Conference, being held at the Warwick Hotel in New York,
NY. Michael M. Goldberg, M.D., Chairman and Chief Executive Officer, will
present on Wednesday, September 7, 2005, at 2:05 p.m. EDT.
The presentation will be broadcast live via the Internet. You may access
the presentation by visiting the investor relations portion within the
Emisphere Technologies, Inc. web site: http://www.emisphere.com/ir.asp or directly at
http://www.internetvideochannel.com/oppenheimer/diabetes.htm . Please visit
the site at least five minutes prior to start time for instructions. A replay
will be available through October 7, 2005. Corresponding slides will also be
posted to the investor relations portion of Emisphere's web site.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the
oral delivery of otherwise injectable drugs. Emisphere's business strategy is
to develop oral forms of injectable drugs, either alone or with corporate
partners, by applying its proprietary eligen(R) technology to those drugs or
licensing its eligen(R) technology to partners who typically apply it directly
to their marketed drugs. Emisphere's eligen(R) technology has enabled the oral
delivery of proteins, peptides, macromolecules and charged organics. Emisphere
and its partners have advanced oral formulations or prototypes of salmon
calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and
cromolyn sodium into clinical trials. Emisphere has strategic alliances with
world-leading pharmaceutical companies. For further information, please visit
http://www.emisphere.com.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
http://www.emisphere.com/ir.asp
CONTACT:
Gillian Racine, Investor Relations of
Emisphere Technologies, Inc., +1-914-785-4762, or
gracine@emisphere.com
|
